Hims & Hers Health Inc. (HIMS) Q2 2026 (USD): EPS -0.37 (exp. -0.05), Revenue 753.2mln (exp. 699mln). Q3 revenue view 880-9000mln (exp. 792mln). FY revenue view 3.1-3.3bln (exp. 2.93bln).

• Q2 subscribers 2.9mln (exp. 2.74mln).

The print splits cleanly along the line the stock typically trades on: top line, subscribers, and guidance all came in ahead, while the bottom line missed by a wide margin. For high-growth consumer health names of this kind, the historical pattern is that revenue trajectory and subscriber additions dominate the reaction, with EPS secondary where losses reflect deliberate spend on marketing, fulfilment, or category expansion rather than demand softness. The wide gap between the guided revenue path and prior consensus is the more consequential element: raises of that size have tended to re-anchor the forward multiple discussion, but they also raise the execution bar for subsequent quarters, since guidance-led rallies in this name's peer set have historically faded when the following print fails to confirm. The EPS shortfall will draw questions on margin trajectory and where the incremental spend is going, and the call commentary on cost structure and any regulatory or supply considerations around its compounded offerings will matter more than the headline numbers. Worth noting the Q3 upper bound as printed reads as a likely typo in the wire, which desks will treat accordingly. Net, the established pattern for this kind of mixed print in a heavily shorted, high-beta growth name is a sharp initial move with elevated volatility into the call.